Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group.

Knaus WA, Harrell FE, LaBrecque JF, Wagner DP, Pribble JP, Draper EA, Fisher CJ, Soll L
Crit Care Med. 1996 24 (1): 46-56

PMID: 8565538 · DOI:10.1097/00003246-199601000-00010

MeSH Terms (17)

APACHE Double-Blind Method Female Humans Interleukin-1 Interleukin 1 Receptor Antagonist Protein Male Middle Aged Models, Statistical Recombinant Proteins Risk Assessment Risk Factors ROC Curve Severity of Illness Index Sialoglycoproteins Survival Rate Systemic Inflammatory Response Syndrome

Connections (1)

This publication is referenced by other Labnodes entities: